{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:55Z","timestamp":1792190515205,"version":"4.4.0"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Secukinumab has demonstrated sustained long\u2010term efficacy with a favourable safety profile in various psoriatic disease manifestations in adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Here, the efficacy and safety of two secukinumab dosing regimens [low dose (LD) and high dose (HD)] in paediatric patients with severe chronic plaque psoriasis over one year are reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this multicentre, double\u2010blind study (NCT02471144), patients aged 6 to &lt;18\u00a0years with severe chronic plaque psoriasis were stratified and randomized by weight (&lt;25\u00a0kg, 25 to &lt;50\u00a0kg, \u226550\u00a0kg) and age (6 to &lt;12\u00a0years, 12 to &lt;18\u00a0years) to receive low\u2010dose (LD: 75\/75\/150\u00a0mg) or high\u2010dose (HD: 75\/150\/300\u00a0mg) subcutaneous secukinumab or placebo or etanercept 0.8\u00a0mg\/kg (up to a max of 50\u00a0mg).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 162 patients were randomized to receive secukinumab LD (<jats:italic>n<\/jats:italic>\u00a0=\u00a040) or HD (<jats:italic>n<\/jats:italic>\u00a0=\u00a040), etanercept (<jats:italic>n<\/jats:italic>\u00a0=\u00a041) or placebo (<jats:italic>n<\/jats:italic>\u00a0=\u00a041). The co\u2010primary objectives of the study were met with both secukinumab doses (LD and HD) showing superior efficacy compared to placebo (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001) with respect to PASI 75 response (80.0%, 77.5% vs. 14.6%) and IGA mod 2011, 0 or 1 response (70%, 60% vs. 4.9%) at Week 12. Both secukinumab doses were superior to placebo (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001) with respect to PASI 90 response at Week 12 (72.5%, 67.5% vs. 2.4%). The efficacy of both doses was sustained to Week 52 with secukinumab achieving higher responses vs. etanercept (PASI 75\/90\/100: LD, 87.5%\/75.0%\/40.0% and HD, 87.5%\/80.0%\/47.5.% vs. etanercept, 68.3%\/51.2%\/22.0% and IGA 0 or 1: LD, 72.5% and HD, 75.0% vs. etanercept, 56.1%). The safety profile of secukinumab was consistent with the adult Phase 3 studies, with no new safety signals identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Both doses of secukinumab demonstrated high and sustained efficacy up to Week 52 with a favourable safety profile in paediatric patients with severe chronic plaque psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.17002","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T18:46:28Z","timestamp":1602960388000},"page":"938-947","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52\u2010week results from a Phase 3 double\u2010blind randomized, controlled trial"],"prefix":"10.1111","volume":"35","author":[{"given":"C.","family":"Bodemer","sequence":"first","affiliation":[{"name":"Department of Dermatology H\u00f4pital Necker\u2010Enfants Malades APHP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kaszuba","sequence":"additional","affiliation":[{"name":"DERMED Medical Services Lodz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kingo","sequence":"additional","affiliation":[{"name":"Tartu University Hospital and University of Tartu Tartu Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tsianakas","sequence":"additional","affiliation":[{"name":"Fachklinik Bad Bentheim Bad Bentheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morita","sequence":"additional","affiliation":[{"name":"Nagoya City University Hospital Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rivas","sequence":"additional","affiliation":[{"name":"Dermos Guatemala City Guatemala"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Papanastasiou","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Keefe","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Patekar","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Charef","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cafoncelli","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Papavassilis","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.009092"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15021"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14507"},{"key":"e_1_2_7_6_1","first-page":"187","article-title":"Prevalence of psoriasis in children and adolescents in the United States: a claims\u2010based analysis","volume":"17","author":"Paller AS","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13382"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.049"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/ddg.13936","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents \u2013 Short version part 2","volume":"17","author":"Eisert L","year":"2019","journal-title":"J Deutsch Dermatol Ges"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09593.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5417"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07185.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1476653"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.11.948"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-017-2985-x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2011.10066"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416655705"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14454"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15665"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/ddg.13936","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents \u2013 short version part 2","volume":"17","author":"Eisert L","year":"2019","journal-title":"J Dtsch Dermatol Ges."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.056"},{"key":"e_1_2_7_23_1","unstructured":"Stelara [prescribing information].Horsham PA:Janssen Biotech Inc. November2019."},{"key":"e_1_2_7_24_1","unstructured":"Stelara [summary of product characteristics].High Wycombe Bucks:Janssen\u2010Cilag Ltd January2020."},{"key":"e_1_2_7_25_1","unstructured":"Enbrel [prescribing information].Thousand Oaks CA:Amgen March2020."},{"key":"e_1_2_7_26_1","unstructured":"Enbrel [summary of product characteristics].Bruxelles Belgium:Pfizer Europe MA EEIG November2019."},{"key":"e_1_2_7_27_1","unstructured":"Humira [product of summary characteristics].Berkshire UK:AbbVie Ltd November2019."},{"key":"e_1_2_7_28_1","unstructured":"Taltz [prescribing information].Indianapolis IN:Eli Lilly and Company March2020."},{"key":"e_1_2_7_29_1","unstructured":"Cosentyx [prescribing information].East Hanover NJ:Novartis Pharmaceutical Corporation January2020."},{"key":"e_1_2_7_30_1","unstructured":"Cosentyx [summary of product characteristics].Camberley UK:Novartis Europharm Limited November2019."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"e_1_2_7_35_1","first-page":"S3","article-title":"The role of IL\u201017 in the pathogenesis and treatment of psoriasis","volume":"9","author":"Zeichner JA","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.011"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17002","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:12:20Z","timestamp":1693588340000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/jdv.17002"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17002","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"2020-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}